Symbol over Substance
By Jesse Reynolds,
GeneWatch (Sep-Oct 2009)
| 10. 22. 2009
Despite over a decade of hype, cloning-based stem cell research has offered little in the way of scientific progress. It has been more symbol than substance; more moving target than realistic goal. However, by complicating both politics and policy, is has been a monkey wrench in the gears for progressive advocates of responsible biotechnologies.
Although there had been previous technological and policy developments in reproductive cloning, the 1996 birth of Dolly the Sheep - the first cloned mammal - catalyzed widespread concern and numerous laws about human reproductive cloning throughout the world. It quickly became clear that, outside of a handful of extreme techno-enthusiasts, reproductive human cloning had few defenders. Prohibitions in every nation, and even internationally, seemed to be just around the corner.
But two years after Dolly's birth, scientists led by James Thomson at the University of Wisconsin isolated human embryonic stem cells. These cells' power to differentiate into any tissue type - a characteristic called pluripotency - represented the foundation of a potential new type of medicine, in which cellular therapies could be used to repair the...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...